Creso Pharma Limited
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Creso Pharma Limited (ASX:CPH; OTCQB:COPHF), founded in 2015 and headquartered in Nedlands, Western Australia, with key operations in Switzerland, develops, registers, and commercializes pharmaceutical-grade cannabis and hemp-derived nutraceutical products and treatments for human and animal health; its core offerings span Creso Animal Health products including anibidiol® for pets; nutraceutical lines such as cannaQIX®, cannaPEAL®, and cannaDOL® targeting stress, pain, sleep, and mental functions; topical gels and cosmetics; therapeutics like CBD-based formulations; and lifestyle supplements, all leveraging proprietary technologies for enhanced cannabinoid bioavailability and absorption. The company serves consumer and patient markets across Europe, Middle East, North America, Australia, Canada, Colombia, Israel, and other regions, deriving primary revenue from Europe and the Middle East while expanding into recreational cannabis via subsidiary Mernova Medical Inc. and psychedelics through Halucenex Life Sciences Inc. Recent major developments include the 2022 acquisition of Sierra Sage Herbs LLC, providing established US revenue-generating CBD operations, supply chain, and retail distribution channels; a definitive agreement to acquire Health House International Limited (ASX:HHI) for synergistic plant-based product expansion; a non-exclusive distribution partnership in Australia, Taiwan, and Singapore announced in 2022; and a 2021 merger agreement with Red Light Holland Corp to form The HighBrid Lab, targeting US cannabis and psilocybin markets with A$48 million post-transaction cash balance, alongside a US OTCQB listing under COPHF to attract institutional investors.
Melodiol Global Health Stock Scheduled to Reverse Split on Wednesday, June 5th (OTCMKTS:COPHF)
Cannabis stocks slump on SAFE Banking Act Senate hearing and mixed quarterly earnings
Creso Pharma psychedelics subsidiary Halucenex Life Sciences broadens scope ahead of Phase 2 clinical trials
Creso Pharma subsidiary on official list to provide psilocybin to Canadian doctors
Australian Creso Pharma To Enter US CBD Market Via $21M Acquisition Of Sierra Sage Herbs
Creso Pharma pushes into US CBD market with revenue-generating acquisition
Creso Pharma psychedelics subsidiary Halucenex lodges CTA to test efficacy of psilocybin on treatment-resistant PTSD
Creso Pharma has eye on North America with new crop of cannabis-credentialled executives
Creso Pharma subsidiary Halucenex invited to become Special Access Program drug supplier in Canada
Creso Pharma on-track for quarter-on-quarter revenue growth as Mernova records strong cannabis sales
Creso Pharma subsidiary secures upgrade to its Controlled Drugs and Substances Dealer's Licence
Creso Pharma completes integration of Creso ImpACTIVE Ltd assets as it continues to broaden US horizons
Creso Pharma delivers 126% revenue growth in Switzerland with more purchase orders on the way
Creso Pharma's psychedelics company one step closer to Phase II trial
Creso Pharma appoints leading cannabis consultant to increase R&D capacity
Creso Pharma to expand into burgeoning Swiss medicinal cannabis market
Creso Pharma looks to expand North American footprint via CBD asset acquisition ahead of dual listing
Creso Pharma subsidiary Mernova's THC content testing on new cannabis strains exceeds industry average
Creso Pharma's psychedelics subsidiary proceeds to stability testing ahead of clinical trial
Creso Pharma subsidiary Mernova rakes in A$800,000 in new artisanal cannabis product orders